检索结果-南通市图书馆

Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer:A meta-analysis

引用

World Journal of Gastrointestinal Surgery 2024年第3期16卷 921-931页

作者： Xiao-Yan Liu Hong-Nian Pan Yue Yu Cheeloo College of Medicine Shandong UniversityJinan 250012Shandong ProvinceChina Department of Gastroenterology The First Affiliated Hospital of USTCDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001Anhui ProvinceChina Department of Gastroenterology The Lu’an Hospital Affiliated to Anhui Medical UniversityThe Lu’an People's HospitalLu’an 237000Anhui ProvinceChina

BACKGROUND advanced pancreatic cancer is resistant to chemotherapeutic drugs,resulting in limited treatment efficacy and poor *** administration of the chemotherapeutic gemcitabine and erlotinib is considered a potential first-line treatment for advanced pancreatic ***,their comparative benefits and potential risks remain *** To assess the clinical efficacy and safety of erlotinib combined with other chemotherapy regimens for the treatment of advanced pancreatic *** Literature on the clinical efficacy and safety of erlotinib combined with chemotherapy for advanced pancreatic cancer was retrieved through an online *** retrieved literature was subjected to a methodological qualitative assessment and was analyzed using the RevMan 5.3 *** randomized controlled trials involving 2444 patients with advanced pancreatic cancer were included in the *** Compared with chemotherapeutic treatment,erlotinib combined with chemotherapy significantly prolonged the progression-free survival time of pancreatic cancer patients[hazard ratio(HR)=0.78,95%CI:0.66-0.92,P=0.003].Meanwhile,the overall survival(HR=0.99,95%CI:0.72-1.37,and P=0.95)and disease control rate(OR=0.93,95%CI:0.45-0.91,P=0.84)were not significantly *** terms of safety,the erlotinib and chemotherapy combination was associated with a significantly higher risk of diarrhea(OR=3.59,95%CI:1.63-7.90,Ppancreatic cancer,but does not improve survival benefit or disease control rate,and can increase the risk of diarrhea and rash.

关键词： Erlotinib Chemotherapy advanced pancreatic cancer Efficacy Safety Meta-analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The real-world study of the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer in China

引用

Journal of Pancreatology 2024年第1期7卷 1-9页

作者： Jiujie Cui Qihan Fu Xiaobing Chen Yanling Wang Qi Li Feng Wang Zhihua Li Guanghai Dai Yusheng Wang Hongmei Zhang Houjie Liang Jun Zhou Liu Yang Fenghua Wang Leizhen Zheng Xiaofeng Chen Ping Gong Jiang Liu Ying Yuan Lin Wang Yuejuan Cheng Jun Zhang Yuhong Zhou Weijian Guo Xianbao Zhan Zhengyun Zou Da Li Shan Zeng Enxiao Li Zhiwei Li Zan Teng Dan Cao Jie Kan Jianping Xiong Ming Quan Jiayu Yao Haiyan Yang Liwei Wang Department of Medical Oncology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghaiChina Department of Medical Oncology The First Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhouChina Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina Department of Medical Oncology Shanghai General HospitalShanghai Jiao Tong UniversityShanghaiChina Department of Medical Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen UniversityGuangzhouChina Medical Oncology Chinese PLA General HospitalBeijingChina Department of Gastrointestinal Oncology Shanxi Provincial Cancer HospitalAffiliated to Shanxi Medical UniversityTaiyuanChina Department of Clinical Oncology Xijing HospitalAir Force Medical UniversityXi’anChina Department of Oncology and Southwest cancer Center Southwest HospitalThird Military Medical University(Army Military Medical University)ChongqingChina Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijingChina cancer Center Department of Medical OncologyZhejiang Provincial People’s HospitalPeople’s Hospital of Hangzhou Medical CollegeHangzhouChina Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongChina Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of MedicineShanghaiChina Department of Oncology the First Affiliated Hospital with Nanjing Medical UniversityNanjingChina Department of Oncology The First Affiliated HospitalSchool of MedicineShihezi UniversityShiheziChina Department of Oncology People’s Hospital of Xinjiang Uygur Autonomous RegionXinjiangChina Department of Medical Oncology t

Objective:Real-world diagnostic and treatment data for pancreatic cancer in China are *** such,the present study investigated the clinical characteristics,diagnosis,and treatment of advanced pancreatic cancer(including locally advanced and metastatic disease)in the Hospital-based advanced pancreatic cancer Cohort in China of the China Pancreas Data Center ***:A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a *** entire course of real-world pancreatic cancer management was ***:The proportion of patients with advanced pancreatic cancer was higher among males than females(62.4%vs 37.6%,respectively).Patients typically had a history of hypertension(30.8%),diabetes(21.6%),and cholangitis(20.2%).Abdominal pain(51.6%),abdominal distension(27.1%),jaundice(20.1%),and weight loss(16.3%)were the main symptoms observed in patients with advanced pancreatic cancer in this *** carbohydrate antigen(CA)19-9 is one of the most common tumor *** the present study,2562 patients underwent first-line *** median progression-free survival(PFS)for patients undergoing first-line therapy was 4.1 *** major options for first-line therapy included gemcitabine(GEM)plus S-1(GS/X)(23.4%),nab-paclitaxel plus GEM(AG)(18.1%),oxaliplatin,irinotecan,and leucovorin-modulated fluorouracil(FOLFIRINOX;11.9%),nab-paclitaxel plus S-1(AS)(8.9%),and GEM combined with oxaliplatin/cisplatin(GEMOX/GP)(7.6%).The AS and GS/X regimens were associated with the highest PFS ***:This is the first study to report multicenter,real-world data regarding advanced pancreatic cancer in *** revealed that real-world treatment options differed from guideline recommendations,and PFS was shorter than that in previously reported *** intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

关键词： advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Systemic treatment for advanced pancreatic cancer

引用

World Journal of Gastrointestinal Oncology 2023年第10期15卷 1691-1705页

作者： Wattana Leowattana Pathomthep Leowattana Tawithep Leowattana Department of Clinical Tropical Medicine Mahidol UniversityRachatawee 10400BangkokThailand Department of Medicine Srinakharinwirot UniversityWattana 10110BangkokThailand

pancreatic cancer is a deadly disease with an extremely poor 5-year survival rate due to treatment resistance and late-stage *** numerous years of research and pharmaceutical development,these figures have not *** options for advanced pancreatic cancer are still *** illness is typically detected at a late stage,making curative surgical resection *** is the most commonly utilized technique for treating advanced pancreatic cancer but has poor *** therapy and immunotherapy have made significant progress in many other cancer types and have been proven to have extremely promising possibilities;these therapies also hold promise for pancreatic *** is an urgent need for research into targeted treatment,immunotherapy,and cancer *** this review,we emphasize the founda-tional findings that have fueled the therapeutic strategy for advanced pancreatic *** also address current advancements in targeted therapy,immuno-therapy,and cancer vaccines,all of which continue to improve the clinical outcome of advanced pancreatic *** believe that clinical translation of these novel treatments will improve the low survival rate of this deadly disease.

关键词： Systemic treatment advanced pancreatic cancer Personalized medicine Biomarkers Chemotherapy Targeted therapy Immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer:a systematic review and meta-analysis

引用

Journal of Pancreatology 2022年第2期5卷 49-57页

作者： Chengqing Li Wenyi Guo Shihong Chen Jianwei Xu Feng Li Lei Wang Department of pancreatic Surgery General SurgeryQilu Hospital of Shandong UniversityJinanPeople’s Republic of China

Chemotherapy is the mainstay of treatment for advanced pancreatic cancer(stageⅢ/Ⅳ).However,conventional systemic intravenous chemotherapy(SIC)has been unsatisfactory for pancreatic *** recent years,regional arterial infusion chemotherapy(RAIC)has been clinically used as a new chemotherapy regimen for the treatment of advanced pancreatic cancer,but its efficacy is *** purpose of this study was to evaluate the clinical efficacy and safety of *** searched literatures in databases such as PubMed,EMBASE,Cochrane Library,Web of Science,and *** screening,this meta-analysis finally included 9 randomized controlled trials(RCTs)with 444 patients(230 RAIC and 214 SIC).We used the Cochrane Risk of Bias 2.0 tool to assess risk of bias for included *** were overall survival(OS),overall response rate(ORR),adverse events rate(AER),and pain remission *** indicators used relative risk(RR)and its 95%confidence interval(CI)as effect analysis *** results showed that RAIC had some advantages over SIC in terms of ORR,OS,incidence of leukopenia,and pain *** conclusion,compared with SIC,RAIC has better clinical efficacy and lower toxicity in the treatment of advanced pancreatic cancer.

关键词： advanced pancreatic cancer Adverse events rate Clinical efficacy Meta-analysis Regional arterial infusion chemo-therapy Systemic intravenous chemotherapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer

引用

World Journal of Gastroenterology 2008年第34期14卷 5311-5315页

作者： Hisato Igarashi Tetsuhide Ito Ken Kawabe Terumasa Hisano Yoshiyuki Arita Toyoma Kaku Ryoichi Takayanagi Department of Medicine and Bioregulatory Science Graduate School of Medical ScienceKyushu University

AIM:To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. METHODS: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m2, was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed. RESULTS: Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60%, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50% showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, ***: Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.

关键词： advanced pancreatic cancer Chemoradio-therapy Gemcitabine Radiosensitizer Tumor marker

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

引用

World Journal of Gastrointestinal Oncology 2020年第3期12卷 332-346页

作者： Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey Department of Medical Oncology Besançon University HospitalBesançon F-25030France University Bourgogne Franche-Comté INSERMEFS BFCUMR1098Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et GéniqueBesançon F-25000France INSERM CIC-1431 Clinical Investigation Center in BiotherapyBesançon University HospitalBesançon F-25030France Department of Medical Oncology Lille University HospitalLille F-59000France Department of Medical Oncology Nord Franche-ComtéHospitalMontbéliard F-25020France Methodological and Quality of Life in Oncology Unit Besançon University HospitalBesançon F-25030France Department of Gastroenterology Besançon University HospitalBesançon F-25030France

BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal *** To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical *** Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)*** consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 ***-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were *** Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,*** propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse *** growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both *** FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with *** low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.

关键词： advanced pancreatic cancer First-line chemotherapy FOLFOXIRI FOLFIRINOX Propensity score Cohort study

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Babaodan Capsule(八宝丹胶囊)Combined with Qingyi Huaji Formula(清胰化积方)in advanced pancreatic cancer--A Feasibility Study

引用

Chinese Journal of Integrative Medicine 2017年第12期23卷 937-942页

作者： song li-bin gao song zhang ai-qin qian xiang liu lu-ming department of integrative oncology fudan university shanghai cancer centerShanghai 200032China department of oncology shanghai medical collegefudan universityShanghai 200032China department of integrative oncology zhejiang province cancer hospitalHangzhou 310022China

Objective: To observe the clinical effects of Babaodan Capsule(八宝丹, BBD) combined with Qingyi Huaji Formula(清胰化积方, QYHJ) in treating patients with advanced pancreatic cancer. Methods: Eighty-one patients with advanced pancreatic cancer(from January 1, 2013 to December 31, 2014) were enrolled. Patients were assigned to two groups: QYHJ plus BBD group(40 cases) and QYHJ only group(41 cases), and there were no significant differences for other treatment between two groups. The survival and cancer-related symptoms were compared between two groups over two cycles of treatment. Results: The cancer-related symptoms of patients such as ascites, jaundice, pain, abdominal distension, anorexia and Karnofsky performance status of QYHJ plus BBD group were significantly improved as compared with those of the QYHJ group(Padvanced pancreatic cancer. However, it deserves to be further investigated in randomized clinical trials.

关键词： advanced pancreatic cancer Babaodan Capsule Qingyi Huaji Formula Chinese medicine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Therapeutic Evaluation on advanced pancreatic cancer Treated by Integrative Chinese and Western Medicine──Clinical Analysis of 56 Cases

引用

Chinese Journal of Integrated Traditional and Western Medicine 2003年第1期9卷 39-43页

作者：刘鲁明吴良村林胜友杨维鸿郭勇徐颖扉舒琦瑾 Deptment of Oncology Zhejiang Provincial Hospital of TCMHangzhou 310006

Objective: In comparison with chemotherapy, to evaluate therapeutic effects on advanced pancreatic cancer treated by integrative Chinese and western medicine (ICWM) therapies. Methods: Based on the retrospective study of 56 patients with advanced pancreatic cancer, life table was applied to the analysis of patients' survival rate and Xz test to the comparison of therapeutic response between ICWM and chemotherapy groups. Results: The results showed that 1-year survival rate in the ICWM group was 55. 37%±3.24%; 2-year survival rate 34. 61%±16. 31%; 3-year survival rate 25. 96%±24. 64%; 5-year survival rate 25. 96%±24.64%; and median survival period 16. 3 months. However 1-year survival rate in the chemotherapy group was 21. 95%±27. 54% ; 2-year survival rate 7. 31%±27. 54% ; 3-year survival rate 0 % ; and median survival period 7. 5 months. The therapeutic effects between two groups were significantly different (P=0. 004). Further analysis suggested that the reduction of cancer mass in the ICWM group was more than that in chemotherapy group (P=0.049) and the improvement of advanced pancreatic cancer related-symptoms better than that of chemotherapy group (P = 0. 002). Conclusion: The ICWM comprehensive therapy is of important value in the treatment of advanced pancreatic cancer.

关键词： advanced pancreatic cancer integrated traditional Chinese and western medicine clinical study

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Complete response in a patient of advanced pancreatic cancer treated with third-line sintilimab and anlotinib:a case report

引用

Clinical Research Communications 2022年第1期5卷 20-24页

作者： Jiang-Xia Yin Yong-Jie Zhang Ai-Xiang Li Gui-Feng Chen Li-Ping Zhu Zi-Zhi Zhang Department of Medical Oncology Shouguang Hospital of Traditional Chinese MedicineShouguangShandong ProvinceChina

The patient was a 63-year-old female,who was diagnosed with advanced pancreatic cancer with mediastinal lymph node and lung metastases and pleural effusion in June ***-line treatment with 6 cycles of gemcitabine plus tegafur with best response of partial ***-line treatment was 4 cycles of nab-paclitaxel monotherapy ended up with disease ***-line treatment was sintilimab with anlotinib for 10 *** patient's condition has achieved clinical complete remission so far.

关键词： sintilimab anlotinib advanced pancreatic cancer complete response

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy of continuous arterial perfusion chemotherapy combined with transarterial chemoembolization regional arterial thermal perfusion in the treatment of pancreatic cancer with liver metastases

引用

Oncology and Translational Medicine 2023年第4期9卷 176-183页

作者： Zhuo Zhong Jian Yang Jing-Zi Luo Xiong Xie Zhi-Mei Huang De Long Oncology Department Guangzhou Hospital of Integrated Traditional and West Medicine Hepatobiliary Surgery Department Zhujiang Hospital Affiliated to Southern Medical University Clinical Laboratory Department Guangzhou Hospital of Integrated Traditional and West Medicine Minimally Invasive Intervention Department Sun Yat-sen University Cancer Prevention Center

Background:The aim of the study was to investigate the efficacy of continuous transcatheter arterial infusion chemotherapy combined with transarterial chemoembolization(TACE)for the treatment of advanced pancreatic cancer with liver ***:Sixty patients with advanced pancreatic cancer and liver metastases were enrolled in this *** the treatment group,31patients underwent continuous transcatheter arterial infusion chemotherapy combined with TACE regional arterial thermal perfusion,whereas 29 patients included in the control group received intravenous chemotherapy with gemcitabine and *** patients received maintenance chemotherapy with S-1 after 4 cycles of the study *** efficacy,quality of life,survival,and toxicity were ***:Efficacy was better in the treatment group than in the control group,as reflected by the objective remission,partial remission,and disease progression rates(all Ppancreatic cancer and liver metastasis,sugges

关键词： advanced pancreatic cancer Liver metastasis Continuous transcatheter arterial infusion chemotherapy(cTAI) Transcatheter arterial chemoembolization(TACE) Arterial perfusion chemotherapy Efficacy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：